Search

Displaying results 211 - 220 of 392 in total
  1. Drug

    Mipomersen

    go.drugbank.com/drugs/DB05528
    Approved

    It is marketed under the brand name Kynamro in the United States, and the FDA label includes a black box warning of hepatoxicity.

  2. Drug

    AGuIX

    go.drugbank.com/drugs/DB18189
    Investigational

    AGuIX is an investigational brand product consisting of a polysiloxane matrix and gadolinium chelates.

  3. Drug

    Aflibercept

    go.drugbank.com/drugs/DB08885
    ApprovedInvestigational

    [A261130,L47915] Ziv-aflibercept, under the brand name Zaltrap, was developed as an intravenous injection for the treatment of metastatic colorectal cancer, and it was approved by the FDA and EMA in … [L47966,L47971] The intravitreal formulation, under the brand name EYELEA, was approved by the FDA for the treatment of retinopathy of prematurity in preterm infants in February 2023 and for the treatment

  4. Drug

    Hyaluronic acid

    go.drugbank.com/drugs/DB08818
    ApprovedInvestigationalVet approved

    Hyaluronic acid (HA) is an anionic, nonsulfated glycosaminoglycan found in connective, epithelial, and neural tissues; it was first isolated in 1934. Karl Meyer and John Palmer obtained glycosaminoglycan (GAG) from the bovine eye, giving...

  5. Drug

    Efbemalenograstim alfa

    go.drugbank.com/drugs/DB18704
    ApprovedInvestigational

    [A33650,A262172] On November 22, 2023, efbemalenograstim alfa was approved by the FDA under the brand name Ryzneuta for the treatment of chemotherapy-induced neutropenia in adult patients with non-myeloid

  6. Drug

    Asfotase alfa

    go.drugbank.com/drugs/DB09105
    ApprovedInvestigational

    Asfotase Alfa is marketed under the brand name Strensiq® by Alexion Pharmaceuticals, Inc. The annual average price of Asfotase Alfa treatment is $285,000.

  7. Drug

    Gadoteric acid

    go.drugbank.com/drugs/DB09132
    ApprovedInvestigational

    [A263141,A263106] Gadoterate is approved by the FDA under the brand name DOTAREM on 20th March 2013 for intravenous uses with magnetic resonance imaging (MRI) in the brain (intracranial), spine, and

  8. Drug

    Gepirone

    go.drugbank.com/drugs/DB12184
    Approved

    [A261670,A261675,A182315] Gepirone was approved by the FDA on September 28, 2023, under the brand name EXXUA for the treatment of adults with major depressive disorder.

  9. Drug

    Selpercatinib

    go.drugbank.com/drugs/DB15685
    ApprovedInvestigational

    It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc.[L13604] Selpercatinib is also approved by the European Commission.

  10. Drug

    Trastuzumab emtansine

    go.drugbank.com/drugs/DB05773
    ApprovedInvestigational

    Trastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic